2025年11月14日,国家医疗保障局在苏州国际博览中心正式宣布2026年版国家医保药品目录调整结果 1。此次调整共新增107种药品,其中包含51个1类新药,使得医保目录内药品总数达到3331个 1。药明巨诺的CAR-T产品瑞基奥仑赛注射液成功进入基本医保,其原定价为129万元/支,医保支付标准调整为28.86万元/支 1。
本次目录调整引入了“预申报”机制,允许已完成技术审评但尚未获得正式批件的药品提前参与申报,从而推动部分创新药实现“当年获批、当年入保”,显著缩短了上市与进保之间的时间差 1。政策制定过程中重点考量了药品的临床价值、填补保障空白的能力以及医保基金的可承受性,商业健康保险先行支付成为药品进入基本医保的重要参考路径 1。据国家医保局局长章轲披露,目前医保谈判每年带动的药品销售额已超过1700亿元,这一规模是五年前的四倍 1。
China has officially released the results of its 2026 national medical insurance drug catalogue adjustment, adding 107 new medications to the list and bringing the total number of covered drugs to 3,331. 1 Among these additions, 51 are Class 1 new drugs. 1 The inclusion of Chimeric Antigen Receptor T-cell (CAR-T) therapy marks a significant milestone, specifically featuring Relmacabtagene autoleucel injection (Ruiji Olsencar), developed by JW Therapeutics (WuXi Juno). 1 This product was previously priced at 1.29 million yuan per dose but will now have an adjusted medical insurance payment standard of 288,600 yuan per dose. 1 The announcement and detailed interpretation of these changes took place on November 14, 2025, at the Suzhou International Expo Center, led by the National Healthcare Security Administration. 1
Accelerated Approval via "Pre-declaration" Mechanism
A key structural change in this year’s adjustment is the implementation of a "pre-declaration" mechanism, which allows pharmaceutical products that have completed technical review but not yet received formal approval certificates to apply early. 1 This innovation significantly shortens the time gap between a drug’s market approval and its entry into medical insurance coverage, enabling some innovative medicines to be both approved and included in the insurance catalogue within the same year. 1 According to Zhang Ke, head of the National Healthcare Security Administration, annual sales revenue generated by drugs negotiated into the medical insurance scheme exceeds 170 billion yuan, a figure that is four times higher than it was five years ago. 1
Policy Focus on Clinical Value and Financial Sustainability
The criteria for inclusion in the 2026 catalogue emphasize major clinical significance, filling gaps in healthcare coverage, and ensuring affordability for the insurance fund. 1 Commercial health insurance participation is increasingly viewed as a preliminary pathway or reference factor for drugs seeking entry into basic medical insurance. 1 The policy direction aims to balance patient access with fund sustainability, encouraging pharmaceutical companies to achieve reasonable price returns through genuine innovation rather than speculative pricing. 1
评论
还没有评论,欢迎留下第一条。